Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ONL1204
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Johnson & Johnson
Deal Size : $65.0 million
Deal Type : Series D Financing
ONL Therapeutics Closes $65 Million in Oversubscribed Series D Financing
Details : The funds will advance the development of ONL1204 Ophthalmic Solution by initiating a Phase 2 global study for treating GA associated with dry age-related macular degeneration.
Brand Name : ONL1204
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 13, 2024
Lead Product(s) : ONL1204
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Johnson & Johnson
Deal Size : $65.0 million
Deal Type : Series D Financing
Lead Product(s) : ONL1204
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ONL1204 is a novel, first-in-class small molecule Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death that occurs across a range of retinal diseases and conditions.
Brand Name : ONL1204
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 28, 2023
Lead Product(s) : ONL1204
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ONL1204
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ONL1204 is a novel, Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death that occurs across a range of retinal diseases and conditions. It is being investigated in patients with macula-off rhegmatogenous retinal ...
Brand Name : ONL1204
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 12, 2023
Lead Product(s) : ONL1204
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ONL1204
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Bios Partners
Deal Size : $15.0 million
Deal Type : Series C Financing
Details : Proceeds from the financing will primarily support the advancement of ONL1204 Ophthalmic Solution, a novel, first-in-class small molecule Fas inhibitor, into a Phase 2 clinical trial in patients with macula-off rhegmatogenous retinal detachment (RRD).
Brand Name : ONL1204
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 08, 2023
Lead Product(s) : ONL1204
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Bios Partners
Deal Size : $15.0 million
Deal Type : Series C Financing
Lead Product(s) : ONL1204
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ONL1204 is a novel, first-in-class small molecule Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death that occurs across a range of retinal diseases and conditions.
Brand Name : ONL1204
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 13, 2023
Lead Product(s) : ONL1204
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ONL1204
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ONL1204 is a novel, first-in-class small molecule Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death that occurs across a range of retinal diseases and conditions.
Brand Name : ONL1204
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 01, 2023
Lead Product(s) : ONL1204
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ONL1204
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ONL1204 is a novel, first-in-class small molecule Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death that occurs across a range of retinal diseases and conditions.
Brand Name : ONL1204
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 26, 2023
Lead Product(s) : ONL1204
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ONL1204
Therapeutic Area : Ophthalmology
Study Phase : IND Enabling
Sponsor : ONL Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ONL1204 Ophthalmic Solution is a novel, first-in-class small peptide Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death that occurs in a range of retinal diseases and conditions.
Brand Name : ONL1204
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 12, 2022
Lead Product(s) : ONL1204
Therapeutic Area : Ophthalmology
Highest Development Status : IND Enabling
Sponsor : ONL Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ONL1204
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Bios Partners
Deal Size : $46.9 million
Deal Type : Series B Financing
Details : This funding supports the completion of a Phase 1 study in retinal detachment with ONL’s lead compound ONL1204. In addition, the funding will advance ONL1204 in two chronic indications, glaucoma and dry age-related macular degeneration.
Brand Name : ONL1204
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 22, 2020
Lead Product(s) : ONL1204
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Bios Partners
Deal Size : $46.9 million
Deal Type : Series B Financing
LOOKING FOR A SUPPLIER?